Hepatitis B virus infection in US correctional facilities: A review of diagnosis, management, and public health implications

Journal of Urban Health

Volumn 86, Issue 2, 2009, Pages 263-279

  Gupta, Shaili ^a   Altice, Frederick L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B; Correctional institutions; Cost benefit; Entecavir; Hepatitis B virus; HIV; Injection drug users; Lamivudine; Prisons; Treatment guidelines; Treatment of HBV

Indexed keywords

ADULT; CLINICAL PROTOCOLS; CONTINUITY OF PATIENT CARE; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PRISONERS; PUBLIC HEALTH; UNITED STATES;

EID: 61449157194     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-008-9338-z     Document Type: Review

References (81)

1. Bureau of Justice Statistics, US Department of Justice. Bureau of Justice Statistics, 2006. Available at: http://www.ojp.usdoj.gov/bjs/prisons.htm. Accessed Dec 21, 2007.
2. Harrison PM, Beck AJ. Prisoners in 2005. Washington DC: US Department of Justice, Bureau of Justice Statistics; 2006.
3. TM Hammett MP Harmon W Rhodes 2002 The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997 Am J Public Health 92 1789 1794
4. FL Altice MA Marinovich K Khoshnood K Blankenship S Springer P Selwyn 2005 Correlates of HIV Infection Among Incarcerated Women J Urban Health 82 2 312 326
5. Health Status of Soon-to-be-Released Inmates. A Report to Congress, vol. 2. Washington, DC: National Commission on Correctional Health Care; 2002.
6. TJ Conklin T Lincoln TP Flanigan 1998 A public health model to connect correctional health care with communities Am J Public Health 88 8 1249 1250
7. Altice FL, Springer SA. In: Mayer K, Pfizer HF, eds. Management of HIV/AIDS in Correctional Settings The AIDS Pandemic: Impact on Science and Society. San Diego, CA: Elsevier; 2005.
8. World Health Organization (WHO). Wkly Epidemiol Rec 79(28):253-264; 2004.
9. GM McQuillan PJ Coleman D Kruszon-Moran LA Moyer SB Lambert HS Margolis 1999 Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994 Am J Public Health 89 14 18
10. CDC. US disease burden data 1980-2006. Available at: http://www.cdc.gov/ ncidod/diseases/hepatitis/resource/index.htm#surveillance. Accessed on Oct 30, 2007.
11. A Khan S Goldstein I Williams B Bell E Mast 2000 Opportunities for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings Antivir Ther 5 suppl 1 22
12. ST Goldstein MJ Alter IT Williams 2002 Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs J Infect Dis 185 713 719
13. HF Hull LH Lyons JM Mann SC Hadler R Steece MR Skeels 1985 Incidence of hepatitis B in the penitentiary of New Mexico Am J Public Health 75 1213 1214
14. Centers for Disease Control and Prevention 2004 Transmission of hepatitis B virus in correctional facilities-Georgia, January 1999-June 2002 MMWR Morb Mortal Wkly Rep 53 30 678 681
15. Centers for Disease Control and Prevention 2001 Hepatitis B outbreak in a state correctional facility, 2000 MMWR Morb Mortal Wkly Rep 50 25 529 532
16. Khan A, Simard E, Wurtzel H, et al. The prevalence, risk factors, and incidence of hepatitis B virus infection among inmates in a state correctional facility [Abstract]. In: Program and abstracts of the 130th Annual Meeting of the American Public Health Association, Philadelphia, Pennsylvania, 2002.
17. Ruiz JD, Mikanda J. Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California Correctional System. California Department of Health Services, Office of AIDS, HIV/AIDS Epidemiology Office, March 1996.
18. Mikl J, Dzierbicki A, Smith PF, Greifinger R, Wright L, Morse DL. Trends in HIV infection rates among New York State (NYS) Prison Inmates, 1987-97. Poster abstract no. 23516 presented at 12th World AIDS Congress, June 30, 1998, Geneva, Switzerland.
19. C Weinbaum R Lyerla HS Margolis 2003 Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention MMWR Recomm Rep 52 RR-1 1 36
20. Macalino GE, Salas CM, Towe CW, et al. Incidence and community prevalence of HIV and other blood borne pathogens among incarcerated women in Rhode Island [Abstract]. Presented at the National HIV Prevention Conference. Atlanta, GA: US Department of Health and Human Services, CDC; 1999.
21. A Charuvastra J Stein B Schwartzapfel 2001 Hepatitis B vaccination practices in state and federal prisons Public Health Rep 116 203 209
22. BJ McMahon WL Alward DB Hall 1985 Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state J Infect Dis 151 599 603
23. Iloeje UH, Yang HI, Su J. HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B (CHB) patients: an update from the R.E.V.E.A.L.-HBV Study. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, MA. Abstract 907.
24. CJ Chu EB Keeffe SH Han 2003 Hepatitis B virus genotypes in the United States: results of a nationwide study Gastroenterology 125 2 444 451
25. HL Chan AY Hui ML Wong AML Tse LCT Hung JJY Sung 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 1494 1498
26. CJ Chu M Hussain AS Lok 2002 Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C Gastroenterology 122 1756 1762
27. HL Janssen M van Zonneveld H Senturk 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 123 129
28. V Di Marco O Lo Iacono C Camma 1999 The long-term course of chronic hepatitis B Hepatology 30 257 264
29. G Fattovich G Giustina SW Schalm 1995 Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis Hepatology 21 77 82
30. HI Yang SN Lu YF Liaw 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174
31. CJ Chen HI Yang J Su 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 1 65 73
32. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686
33. SH Ahn KH Han JY Park 2000 Association between hepatitis B virus infection and HLA-DR type in Korea Hepatology 31 6 1371 1373
34. RH Chu LX Ma G Wang LH Shao 2005 Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B World J Gastroenterol 11 30 4753 4757
35. Centers for Disease Control and Prevention 1999 Notice to readers update recommendations to prevent hepatitis B virus transmission-United States MMWR Morb Mortal Wkly Rep 48 2 33 34
36. Centers for Disease Control and Prevention 1991 Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep 40 RR-13 1 25
37. A Charuvastra J Stein B Schwartzapfel 2001 Hepatitis B vaccination practices in state and federal prisons Public Health Rep 116 203 209
38. JA Bick 2007 Infection control in jails and prisons Clin Infect Dis 45 1047 1055
39. WW Bond MS Favero NJ Petersen CR Gravelle JW Ebert JE Maynard 1981 Survival of hepatitis B virus after drying and storage for one week Lancet 1 8219 550 551
40. NJ Petersen DH Barrett WW Bond 1976 Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages Appl Environ Microbiol 32 4 572 574
41. EE Mast CM Weinbaum AE Fiore 2006 A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States-recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults MMWR 55 RR-16 1 33
42. MO Fonseca LW Pang N de Paula Cavalheiro AA Barone M Heloisa Lopes 2005 Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose Vaccine 23 2902 2908
43. NM Wright TL Campbell CN Tompkins 2002 Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users Commun Dis Public Health 5 324 326
44. FL Altice RD Bruce MR Walton MI Buitrago 2005 Adherence to hepatitis B virus vaccination at syringe exchange sites J Urban Health 82 1 151 161
45. AS Lok J McMahon 2007 AASLD practice guidelines for chronic hepatitis B Hepatology 45 2 507 539
46. EB Keeffe DT Dieterich SB Han 2006 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol 4 936 962
47. RG Gish 2007 Improving outcomes for patients with chronic hepatitis B Curr Gastroenterol Rep 9 1 14 22
48. TT Chang GR Gish R de Man 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis N Engl J Med 354 1001 1010
49. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, Massachusetts. Abstract LB2.
50. Buti M, Hadziyannis S, Mathurin P. Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis. Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy
51. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, MA. Abstract LB6.
52. R Gish TT Chang CL Lai 2006 Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naive patients treated with entecavir or lamivudine Hepatology 44 558A
53. Korevaar A, Moucari R, Asselah T, et al. High rates of HBsAg seroconversion in chronic hepatitis B patients responding to interferon therapy: a long-term follow-up study. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston.
54. EB Keeffe S Zeuzem RS Koff 2007 Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 890 897
55. AS Lok CL Lai N Leung 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722
56. Y Benhamou M Bochet V Thibault 1999 Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients Hepatology 30 1302 1306
57. P Marcellin TT Chang SG Lim 2004 Long-term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time Hepatology 40 Suppl 1 665A
58. SJ Hadziyannis NC Tassopoulos EJ Heathcote 2005 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2673 2681
59. CL Lai E Gane CW Hsu 2006 Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine Hepatology 44 4 222A
60. F van Bommel S Mauss D Schurmann 2006 No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years Hepatology 44 Suppl A549
61. HS Lee YH Chung KS Lee 2006 A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 43 982 988
62. S Han TT Chang YC Chao 2007 Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901 Hepatology 46 654A
63. Manns M, Jeffers L, Dalekos G. The antiviral response to tenofovir is comparable in lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic hepatitis B (CHB). Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy
64. van Bömmel F, De Man RA, Petersen J. A Multicenter analysis of antiviral response to tenofovir in HBV mono-infected patients with prior nucleos(t)ide analogue experience. Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy.
65. Berg T, Moller B, Trinh H. Tenofovir (TDF) Versus emtricitabine plus TDF for treatment of chronic hepatitis B in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy
66. CK Hui HY Zhang S Bowden 2008 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B J Hepatol 48 5 714 720
67. JJY Sung JY Lai S Zeuzem 2008 Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 48 5 725 735
68. WM Xu YT Cui L Wang 2004 Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicenter, randomised, double-blind, placebo-controlled study (abstr) Hepatology 40 272A 273A
69. JS Lee S Mullaney R Bronson 1991 Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice J Acquir Immune Defic Syndr 4 9 833 838 doi:10.1097/00126334-199109000-00001
70. CL Thio EC Seaberg R Skolasky Jr 2002 HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) Lancet 360 1921 1926
71. N Bodsworth B Donovan BN Nightingale 1989 The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men J Infect Dis 160 4 577 582
72. Guidelines for Use of Antiretroviral Agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/Guidelines. Accessed on Jan. 2008.
73. McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. Abstract presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007.
74. L Lin C Verslype JF van Pelt M van Ranst J Fevery 2006 Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses Eur J Gastroenterol Hepatol 18 12 1311 1319
75. C Saitta P Pontisso MR Brunetto 2006 Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy Antivir Ther 11 7 931 934
76. J Bruix M Sherman 2005 AASLD practice guidelines: management of hepatocellular carcinoma Hepatology 42 5 1208 1236
77. SA Springer E Pesanti J Hodges T Macura G Doros FL Altice 2004 Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community Clin Infect Dis 38 12 1754 1760
78. CF Kwiatkowski K Fortuin Corsi RE Booth 2002 The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users Addiction 97 10 1289 1294
79. M Pisu MI Meltzer R Lyerla 2002 Centers for Disease Control and Prevention (CDC). Cost-effectiveness of hepatitis B vaccination of prison inmates Vaccine 21 3-4 312 321
80. AD Enriquez MS Campbell KR Reddy 2007 Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis Aliment Pharmacol Ther 26 383 391
81. TA Lee DL Veenstra UH Iloeje SD Sullivan 2004 Cost of chronic hepatitis B infection in the United States J Clin Gastroenterol 38 S144 S147